Published on 11 Dec 2023 on Simply Wall St. via Yahoo Finance
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Could Be 36% Below Their Intrinsic Value...
Key Insights
Corcept Therapeutics' estimated fair value is US$41.23 based on 2 Stage Free Cash Flow to EquityCorcept Therapeutics is estimated to be 36% undervalued based on current share price of US$26.54 Analyst price target for CORT is US$36.83 which is 11% below our fair value estimate
Does the December share price for Corcept Therapeutics Incorporated (NASDAQ:CORT) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting them back to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.